FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026. The once-daily pill cut LDL by up to 59% in trials. Here’s who it’s for.
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor: A Once-Daily Pill That Cuts LDL Cholesterol as Well as Injectables
by | Jul 20, 2026 | Uncategorized | 0 comments
Recent Comments